These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24442886)

  • 1. Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.
    Dalbeth N; Aati O; Gamble GD; Horne A; House ME; Roger M; Doyle AJ; Chhana A; McQueen FM; Reid IR
    Ann Rheum Dis; 2014 Jun; 73(6):1044-51. PubMed ID: 24442886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
    Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
    Shane E; Cohen A; Stein EM; McMahon DJ; Zhang C; Young P; Pandit K; Staron RB; Verna EC; Brown R; Restaino S; Mancini D
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications.
    Dalbeth N; Doyle A; Boyer L; Rome K; Survepalli D; Sanders A; Sheehan T; Lobo M; Gamble G; McQueen FM
    Rheumatology (Oxford); 2011 Feb; 50(2):410-6. PubMed ID: 21059673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single infusion of zoledronate prevents bone loss after stroke.
    Poole KE; Loveridge N; Rose CM; Warburton EA; Reeve J
    Stroke; 2007 May; 38(5):1519-25. PubMed ID: 17395868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
    Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
    Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
    Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Dalbeth N; Billington K; Doyle A; Frampton C; Tan P; Aati O; Allan J; Drake J; Horne A; Stamp LK
    Arthritis Rheumatol; 2019 Oct; 71(10):1739-1746. PubMed ID: 31081595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.